Advanced glycation end products (AGEs)

Advanced glycation end products (AGEs) are a heterogeneous group of compounds formed through the non-enzymatic reaction between reducing sugars and the amino groups of proteins, lipids, or nucleic acids, a process known as the Maillard reaction (Singh et al., 2014, Korean J Physiol Pharmacol). This formation process is significantly accelerated under conditions of chronic hyperglycemia and oxidative stress, leading to the accumulation of irreversible cross-links in long-lived tissue proteins such as collagen (Ahmed, 2005, Diabetes Obes Metab). AGEs exert pathological effects by altering the structural integrity of the extracellular matrix and by binding to the Receptor for Advanced Glycation End products (RAGE), which triggers pro-inflammatory and pro-oxidant signaling cascades (Vistoli et al., 2013, Free Radic Biol Med). Consequently, the accumulation of AGEs is a critical driver in the pathogenesis of diabetic complications, including nephropathy and retinopathy, as well as neurodegenerative and cardiovascular diseases (Singh et al., 2014, Korean J Physiol Pharmacol). Therapeutic strategies targeting these processes include the use of carbonyl scavengers to prevent AGE formation and "AGE-breakers" designed to cleave existing protein cross-links (Vistoli et al., 2013, Free Radic Biol Med). While several agents have shown promise in preclinical models, clinical development has been challenged by safety concerns and the difficulty of reversing established long-term glycation damage (Ahmed, 2005, Diabetes Obes Metab).

Other names

Maillard reaction productsNon-enzymatic glycation productsGlycation end productsAdvanced glycation end product formation

Inhibition of the non-enzymatic glycation process by scavenging reactive dicarbonyl intermediates (e.g., methylglyoxal), blocking the conversion of Amadori products to AGEs, or cleaving established AGE-derived protein cross-links.